Beta Bionics (NASDAQ:BBNX) Insider Mike Mensinger Sells 4,378 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 4,378 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $55,206.58. Following the sale, the insider directly owned 184,415 shares in the company, valued at approximately $2,325,473.15. The trade was a 2.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Trading Down 2.7%

NASDAQ BBNX opened at $12.45 on Thursday. The business’s 50-day moving average price is $10.83 and its 200 day moving average price is $17.31. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The company has a market capitalization of $554.59 million, a PE ratio of -8.24 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. The company had revenue of $27.63 million during the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. Equities analysts predict that Beta Bionics, Inc. will post -2.19 EPS for the current year.

Institutional Trading of Beta Bionics

Large investors have recently added to or reduced their stakes in the business. Strs Ohio acquired a new position in shares of Beta Bionics during the 1st quarter valued at $29,000. EverSource Wealth Advisors LLC increased its position in shares of Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after purchasing an additional 1,594 shares during the period. Summit Securities Group LLC acquired a new position in shares of Beta Bionics during the 4th quarter valued at $52,000. Legal & General Group Plc increased its position in shares of Beta Bionics by 197.4% during the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after purchasing an additional 2,639 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares during the period.

Wall Street Analysts Forecast Growth

BBNX has been the subject of a number of recent research reports. Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Bank of America reduced their price target on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. The Goldman Sachs Group reduced their price target on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Lake Street Capital set a $20.00 price target on Beta Bionics in a report on Wednesday, February 18th. Finally, Robert W. Baird reduced their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and an average target price of $19.70.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics said it is now publishing near real-time real-world data on its iLet Bionic Pancreas on a public website, which could support investor confidence in the company’s commercial progress and transparency. Article Title
• Neutral Sentiment: Several top executives disclosed stock sales on June 2, including CFO Stephen Feider and insiders Steven Jon Russell, Mark Hopman, and Mike Mensinger. Each sale was relatively small and was stated to be for tax withholding related to vesting equity awards, which makes the transactions less concerning than open-market selling, but the volume may still weigh on sentiment.
• Negative Sentiment: Multiple law firms, including Robbins LLP and Johnson Fistel, announced investigations into Beta Bionics and its officers/directors over possible securities-law violations and investor losses. These headlines suggest litigation risk and can spark concerns about disclosure practices and governance. Article Title
• Negative Sentiment: A shareholder alert said Robbins LLP is investigating whether Beta Bionics executives and directors violated securities laws and breached fiduciary duties, adding to the legal overhang. Article Title
• Negative Sentiment: Johnson Fistel also said it is investigating whether investors suffered losses after Beta Bionics reported slower new patient start growth, highlighting concerns that growth momentum may be decelerating. Article Title

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.